Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin add-on to basal insulin with or without oral antidiabetic drugs in type 2 diabetes
2016-001804-43Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sotagliflozin + background therapy with Placebo + background therapy (2 arms). Primary endpoint: Absolute change from baseline in hemoglobin A1c. Started Jul 2017; status: completed.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-001804-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001804-43.